Compelling evidence from the Ramazzini Institute demonstrates dose-related increases in malignant tumors such as lymphomas, leukemias, and renal carcinomas in rodents at exposure levels near the current ADI, with prenatal exposures showing particular sensitivity [10], while network toxicology studies reveal aspartame’s ability to bind key cancer-related proteins (AKT1, MMP9, CASP3) with high affinity, potentially disrupting cellular pathways involved in gastric carcinogenesis [13]. Here, AKT1 is linked to cancer.